Daina Graybosch
Stock Analyst at Leerink Partners
(0.84)
# 3,775
Out of 4,876 analysts
108
Total ratings
35.9%
Success rate
-10.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $20.60 | -41.75% | 1 | Jun 11, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Market Perform | $47 → $9 | $9.95 | -9.55% | 8 | May 14, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $79.10 | +50.44% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.31 | +52.67% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.61 | +256.51% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $65.35 | -40.32% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $25.76 | +74.69% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.52 | +2,599.06% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.04 | +861.54% | 7 | Jan 6, 2023 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $1.84 | +389.13% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $7.95 | +377.99% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $3.76 | +112.77% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $106.72 | +109.90% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.66 | +1,707.23% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.02 | +1,566.67% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.66 | +442.17% | 4 | Feb 25, 2022 |
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $20.60
Upside: -41.75%
iTeos Therapeutics
May 14, 2025
Downgrades: Market Perform
Price Target: $47 → $9
Current: $9.95
Upside: -9.55%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $79.10
Upside: +50.44%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.31
Upside: +52.67%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.61
Upside: +256.51%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $65.35
Upside: -40.32%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $25.76
Upside: +74.69%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.52
Upside: +2,599.06%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.04
Upside: +861.54%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $1.84
Upside: +389.13%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $7.95
Upside: +377.99%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $3.76
Upside: +112.77%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $106.72
Upside: +109.90%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.66
Upside: +1,707.23%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.02
Upside: +1,566.67%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.66
Upside: +442.17%